Confirmatory evidence of ASXL1 relevance in hematological malignancies was produced by Wang et al. (2014) who showed that heterozygous genetic ASXL1-knockout mice (Asxl1+/−) developed MDS/MPN and by Abdel-Wahab et al. (2013), who reported that hematopoietic cell-specific deletions of Asxl1 induced an MDS-like disease. The gene discussed is ASXL1; the disease is myeloproliferative neoplasm.